

Global Cancer Vaccine Market & Clinical Trials Outlook 2028

<https://marketpublishers.com/r/G1CC18B328DEEN.html>

Date: July 2022

Pages: 600

Price: US\$ 3,300.00 (Single User License)

ID: G1CC18B328DEEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Cancer Vaccine Market & Clinical Trials Outlook 2028 Highlights:

Global and Regional Market Size Insight 2022 Till 2028

Cancer Vaccine Market Insight & Forecast By 10 Countries 2022 Till 2028

Cancer Vaccine Market Insight & Forecast By 10 Different Cancers 2022 Till 2028

Approved Cancer Vaccines Patent, Price, & Dosage Analysis

Insight On More Than 350 Cancer Vaccines in Clinical Trials

Cancer Vaccines Trials Insight By Company, Country and Indication

Insight On More Than 20 Cancer Vaccines Commercially Available In Market

The use of vaccines for the prevention of infectious disease represents one of the greatest achievements in modern medicine. Owing to their advantages, research studies have also focused to explore the potential of vaccines in the prevention or management of chronic diseases including cancer. Cancer vaccine represents unique approach to cancer therapy which alters the interaction of the host and the tumor, enlisting the patient's tumor response to attack cancer cells. Further, the immunologic

memory associated with the administration of vaccines also gained the interest of researchers to invest in this segment.

Till date, both therapeutic as well as preventive cancer vaccines have gained entry into the global market. Several cancer vaccines including Gardasil, Gardasil 9, Cecolin, or Cervarix have been approved to prevent HPV infection which target high risk HPV strains responsible for nearly all cervical cancers and are also linked to some throat, anal, and other cancers. In contrast, Provenge was the first therapeutic vaccine globally approved in 2010 for the management of prostate cancer. Apart from this, CemaVax, Riavax, and Vaxira have also been approved for the management of non-small cell lung cancer and pancreatic cancer. The entrance of vaccines has shown to greatly transform the paradigm of cancer treatment.

Currently, the pipeline of cancer vaccine is highly crowded which are increasingly reporting encouraging success in clinical trials across wide range of cancers. Several vaccines are also awaiting marketing approval or commercialization. For instance, US FDA is currently reviewing BLA application for N-803 plus Bacillus Calmette-Guérin as treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer. Apart from this, Cervac has been approved in India and is expected to be available in the market soon. The presence of wide range of clinical pipeline products indicates strong future presence of the market.

With the continuous research and development activities in this domain, scientists have also developed other enhanced platforms for vaccine development including mRNA vaccines, personalized neoantigen cancer vaccines, stem cells, and others. Although these are present in early stages of clinical development, these represent huge potential across wide range of cancers. Further, the market will also experience growth with the introduction of artificial intelligence algorithms which aid in the precise detection of neoantigens and also factor the early development of companies. Several top players in the market has utilized machine learning to develop their proprietary artificial intelligence algorithm for the characterization of neoantigens and ultimately developing personalized neoantigen cancer vaccines.

In last few years, pharmaceutical companies have also entered into collaboration with artificial intelligence players to develop potential cancer vaccines. For instance in 2022, CureVac entered into research and option agreement with myNEO which will aim to identify specific antigens found on the surface of tumors for the development of vaccines. To achieve this goal, myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify and validate specific

antigen targets predicted to elicit strong immune response. Apart from this, myNEO also collaborated with Abera Bioscience to develop personalized cancer vaccines. Other key players in the global market are Argos Therapeutics, Nykode Therapeutics, Merck, Regeneron, GlaxoSmithKline, CureVac, Dendreon, Sanofi, and OSE Immunotherapeutics.

As per our report findings, the global cancer vaccine market is expected to surpass US\$ 15 Billion by 2028. The significant increase in the growth of market is mainly attributed to encouraging sales of HPV cancer vaccines and rising awareness among individuals regarding the benefits of HPV vaccination. Apart from this, several investigational cancer vaccines have progressed towards late stage clinical trials and are expected to gain market authorization, which will also have a positive impact on the growth of market.

Contents

1. INTRODUCTION TO CANCER VACCINES

2. MECHANISM OF CANCER VACCINES

- 2.1 Idiotypic Cancer Vaccine Mechanism
- 2.2 Cellular Cancer Vaccines Mechanism
- 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
- 2.4 Peptide Cancer Vaccine Mechanism
- 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. GLOBAL CANCER VACCINE MARKET OVERVIEW

- 3.1 Current Market Scenario
- 3.2 Future Market Opportunity

4. CANCER VACCINE MARKET INSIGHT BY REGION

- 4.1 US
- 4.2 Europe
- 4.3 China
- 4.4 Japan
- 4.5 India
- 4.6 South Korea
- 4.7 Australia
- 4.8 Cuba
- 4.9 Canada
- 4.10 UK

5. CANCER VACCINE MARKET INSIGHT BY INDICATION

- 5.1 Human papillomavirus Associated Cancer
- 5.2 Lung Cancer
- 5.3 Pancreatic Cancer
- 5.4 Prostate Cancer
- 5.5 Bladder Cancer
- 5.6 Melanoma
- 5.7 Breast Cancer

- 5.8 Colorectal Cancer
- 5.9 Glioblastoma
- 5.10 Ovarian Cancer

6. APPROVED CANCER VACCINES – PRICE, & DOSAGE ANALYSIS

This Chapter Give Insight On 11 Cancer Vaccine Commercially Available In Market

7. GLOBAL CANCER VACCINES CLINICAL PIPELINE OVERVIEW

- 7.1 By Company
- 7.2 By Country
- 7.3 By Patient Segment/Disease Stage
- 7.4 By Phase

8. GLOBAL CANCER VACCINES CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE

- 8.1 Research
- 8.2 Preclinical
- 8.3 Clinical
- 8.4 Phase-I
- 8.5 Phase-I/II
- 8.6 Phase-II
- 8.7 Phase-III/II
- 8.8 Phase-III
- 8.9 Preregistration
- 8.10 Registered

9. MARKETED CANCER VACCINES CLINICAL INSIGHT BY COMPANY & INDICATION

10. COMPETITIVE LANDSCAPE

- 10.1 Anixa Bioscience
- 10.2 Argos Therapeutics
- 10.3 AstraZeneca
- 10.4 BioNTech
- 10.5 Bristol Myers Squibb

- 10.6 Champions Oncology
- 10.7 CureVac
- 10.8 Elicio Therapeutics
- 10.9 ETheRNA
- 10.10 GlaxoSmithKline
- 10.11 ImmunityBio
- 10.12 Imugene
- 10.13 In3Bio
- 10.14 Merck
- 10.15 Mayo Clinic
- 10.16 Nykode Therapeutics
- 10.17 Regeneron
- 10.18 Roche
- 10.19 TVAX Biomedical
- 10.20 UbiVac
- 10.21 Ultimovacs
- 10.22 VBI vaccines

List Of Figures

LIST OF FIGURES

- Figure 1-1: Categorization & Function of Cancer Vaccines
- Figure 2-1: Classification of Different Types of Cancer vaccines
- Figure 3-1: Global – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 3-2: Cancer Vaccine - Market Size by Region (US\$ Million), 2021
- Figure 3-3: Cancer Vaccine - Market Size by Region (%), 2021
- Figure 3-4: Global – Cancer Vaccine Market Size (US\$ Billion), 2022 - 2028
- Figure 4-1: US – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 4-2: US vs. ROW – Cancer Vaccine Market Size (US\$ Million), 2021
- Figure 4-3: US vs. ROW – Cancer Vaccine Market Size (%), 2021
- Figure 4-4: US – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
- Figure 4-5: Europe – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 4-6: Europe vs. ROW – Cancer Vaccine Market Size (US\$ Million), 2021
- Figure 4-7: Europe vs. ROW – Cancer Vaccine Market Size (%), 2021
- Figure 4-8: Europe – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
- Figure 4-9: China – Market Share of HPV Vaccine Suppliers (%), 2020
- Figure 4-10: China – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 4-11: China – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
- Figure 4-12: Japan – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 4-13: Japan – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
- Figure 4-14: India – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 4-15: India – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
- Figure 4-16: South Korea – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 4-17: South Korea – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
- Figure 4-18: Australia – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 4-19: Australia – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
- Figure 4-20: Cuba – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 4-21: Cuba – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
- Figure 4-22: Canada – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 4-23: Canada – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
- Figure 4-24: UK – Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 4-25: UK – Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
- Figure 5-1: Global – HPV Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 5-2: Global – HPV Cancer Vaccine Market Size (US\$ Million), 2022 - 2028
- Figure 5-3: Global – Lung Cancer Vaccine Market Size (US\$ Million), 2020 & 2021
- Figure 5-4: Global – Lung Cancer Vaccine Market Size (US\$ Million), 2022 - 2028

Figure 5-5: Global – Pancreatic Cancer Vaccine Market Size (US\$ Million), 2020 & 2021

Figure 5-6: Global – Pancreatic Cancer Vaccine Market Size (US\$ Million), 2022 – 2028

Figure 5-7: Global – Prostate Cancer Vaccine Market Size (US\$ Million), 2020 & 2021

Figure 5-8: Global – Prostate Cancer Vaccine Market Size (US\$ Million), 2022 - 2028

Figure 5-9: Global – Bladder Cancer Vaccine Market Size (US\$ Million), 2022 - 2028

Figure 5-10: Global – Melanoma Vaccine Market Size (US\$ Million), 2025 - 2028

Figure 5-11: Global – Breast Cancer Vaccine Market Size (US\$ Million), 2024 - 2028

Figure 5-12: Global – Colorectal Cancer Vaccine Market Size (US\$ Million), 2025 – 2028

Figure 5-13: Global – Glioblastoma Vaccine Market Size (US\$ Million), 2025 - 2028

Figure 5-14: Global – Ovarian Cancer Vaccine Market Size (US\$ Million), 2025 - 2028

Figure 6-1: Gardasil – Approval Year by Region

Figure 6-2: Gardasil 9 – Approval Year by Region

Figure 6-3: US – Gardasil Approval Year by Indication

Figure 6-4: Canada – Gardasil Approval Year by Indication

Figure 6-5: Gardasil 9 – Patent Expiration Year by Region

Figure 6-6: US – Cost of 5ml & Per Unit Cost of Gardasil 9 Intramuscular Suspension (US\$), July'2022

Figure 6-7: UK – Per Unit Cost of Gardasil & Gardasil 9 Injection (GBP/US\$), July'2022

Figure 6-8: South Korea – Per Unit Cost of Gardasil Injection (KRW/US\$), July'2022

Figure 6-9: Global – Gardasil/ Gardasil 9 Sales Value (US\$ Million), Q1'2021 & Q1'2022

Figure 6-10: Global – Gardasil/ Gardasil 9 Sales Value (US\$ Million), 2018 - 2021

Figure 6-11: Global – Gardasil/ Gardasil 9 Quarterly Sales Value (US\$ Million), 2021

Figure 6-12: Global – Gardasil/ Gardasil 9 Quarterly Sales Value (US\$ Million), 2020

Figure 6-13: Cervarix – Approval Year by Region

Figure 6-14: UK – Per Unit Cost of Cervarix Injection (GBP/US\$), July'2022

Figure 6-15: UK – Cost of Single Cycle & Total Cost of Treatment with Cervarix (GBP/US\$), July'2022

Figure 6-16: South Korea – Per Unit Cost of Cervarix Injection (KRW/US\$), July'2022

Figure 6-17: Cervarix – Sales Value by Region (Euro/US\$ Million), Q1'2022

Figure 6-18: Cervarix – Sales Value by Region (%), Q1'2022

Figure 6-19: Global – Cervarix Sales Value (Euro/US\$ Million), 2019 - 2021

Figure 6-20: Europe – Cervarix Sales Value (Euro/US\$ Million), 2019 - 2021

Figure 6-21: Cervarix – Sales Value by Region (Euro/US\$ Million), 2021

Figure 6-22: Cervarix – Sales Value by Region (%), 2021

Figure 6-23: US – Cost of 250ml & Per Unit Cost of Proenge Intravenous Suspension (US\$), July'2022

Figure 6-24: India – Per Unit Cost of Mycidac-C Injection (INR/US\$), July'2022

Figure 7-1: Global - Number of Cancer Vaccines in Clinical Trials by Company, 2022 till 2028

Figure 7-2: Global - Number of Cancer Vaccines in Clinical Trials by Country, 2022 till 2028

Figure 7-3: Global - Number of Cancer Vaccines Clinical Trials by Disease Stage, 2022 till 2028

Figure 7-4: Global - Number of Cancer Vaccine in Clinical Trials by Phase, 2022 till 2028

I would like to order

Product name: Global Cancer Vaccine Market & Clinical Trials Outlook 2028

Product link: <https://marketpublishers.com/r/G1CC18B328DEEN.html>

Price: US\$ 3,300.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1CC18B328DEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970